Chan School of Public Health, men who consumed more antioxidant-rich foods showed improved sperm motility and morphology
Today, Novo Nordisk estimates that just under 20 million people are treated with GLP-1 drugs.4 Given a well-stocked pipeline, a substantial global addressable population (the obese population alone is projected to exceed 1.2 billion by 20305), and in light of the very beneficial clinical profile of these drugs, it is plausible that over 100 million patients worldwide will be treated with GLP-1s in the near future
Nevertheless, the clinical application of multi-receptor agonists in adolescents requires caution, as long-term safety, developmental outcomes, and real-world adherence data in pediatric populations are still lacking
Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Alsayegh AA, Almohmadi NH, et al